A peptide's perspective on antigen presentation to the immune system

Nature Chemical Biology

Volumn 9, Issue 12, 2013, Pages 769-775

  Neefjes, Jacques ^a   Ovaa, Huib ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE; BINDING PROTEIN; CHAPERONE; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; PEPTIDE FRAGMENT; PROTEOME; TOLL LIKE RECEPTOR 9;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; CELL SURFACE; CRYSTAL STRUCTURE; CYTOSOL; CYTOTOXIC T LYMPHOCYTE; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GLYCOSYLATION; HEAVY CHAIN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE TRANSPLANTATION;

ANIMALS; ANTIGENS; MAJOR HISTOCOMPATIBILITY COMPLEX; MODELS, MOLECULAR; PEPTIDES; PROTEIN CONFORMATION; PROTEIN SUBUNITS;

EID: 84887938115     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1391     Document Type: Review

References (69)

1. Reinherz, E.L. et al. The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286, 1913-1921 (1999).
2. Garcia, K.C. et al. An ab T cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex. Science 274, 209-219 (1996).
3. Lo, W.L. & Allen, P.M. Self-peptides in TCR repertoire selection and peripheral T cell function. Curr. Top. Microbiol. Immunol. (2013).
4. Neefjes, J., Jongsma, M.L., Paul, P. & Bakke, O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11, 823-836 (2011).
5. Cho, J.H. & Gregersen, P.K. Genomics and the multifactorial nature of human autoimmune disease. N. Engl. J. Med. 365, 1612-1623 (2011).
6. Yewdell, J.W., Reits, E. & Neefjes, J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat. Rev. Immunol. 3, 952-961 (2003).
7. Murata, S., Takahama, Y. & Tanaka, K. Thymoproteasome: probable role in generating positively selecting peptides. Curr. Opin. Immunol. 20, 192-196 (2008).
8. Nitta, T., Murata, S., Ueno, T., Tanaka, K. & Takahama, Y. Thymic microenvironments for T-cell repertoire formation. Adv. Immunol. 99, 59-94 (2008).
9. Kloetzel, P.M. & Ossendorp, F. Proteasome and peptidase function in MHCclass- I-mediated antigen presentation. Curr. Opin. Immunol. 16, 76-81 (2004).
10. Cascio, P., Hilton, C., Kisselev, A.F., Rock, K.L. & Goldberg, A.L. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J. 20, 2357-2366 (2001).
11. Reits, E. et al. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20, 495-506 (2004).
12. Reits, E. et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 18, 97-108 (2003).
13. Neefjes, J.J., Momburg, F. & Hammerling, G.J. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 261, 769-771 (1993).
14. Momburg, F., Roelse, J., Hammerling, G.J. & Neefjes, J.J. Peptide size selection by the major histocompatibility complex-encoded peptide transporter. J. Exp. Med. 179, 1613-1623 (1994).
15. Chang, S.C., Momburg, F., Bhutani, N. & Goldberg, A.L. The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a "molecular ruler" mechanism. Proc. Natl. Acad. Sci. USA 102, 17107-17112 (2005).
16. Ortmann, B. et al. A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science 277, 1306-1309 (1997).
17. Roelse, J., Gromme, M., Momburg, F., Hammerling, G. & Neefjes, J. Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J. Exp. Med. 180, 1591-1597 (1994).
18. Romagnoli, P. & Germain, R.N. The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J. Exp. Med. 180, 1107-1113 (1994).
19. Ghosh, P., Amaya, M., Mellins, E. & Wiley, D.C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378, 457-462 (1995).
20. Pos, W. et al. Crystal structure of the HLA-DM-HLA-DR1 complex defines mechanisms for rapid peptide selection. Cell 151, 1557-1568 (2012).
21. Denzin, L.K. & Cresswell, P. HLA-DM induces CLIP dissociation from MHC class II ab dimers and facilitates peptide loading. Cell 82, 155-165 (1995).
22. Roche, P.A. & Cresswell, P. Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc. Natl. Acad. Sci. USA. 1991. 88: 3150-3154. J. Immunol. 187, 1076-1080 (2011).
23. J. Immunol. 187, 1076-1080 (2011).
24. Stanfield, R.L. & Wilson, I.A. Protein-peptide interactions. Curr. Opin. Struct. Biol. 5, 103-113 (1995).
25. Spee, P. & Neefjes, J. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur. J. Immunol. 27, 2441-2449 (1997).
26. Lammert, E., Stevanovic, S., Brunner, J., Rammensee, H.G. & Schild, H. Protein disulfide isomerase is the dominant acceptor for peptides translocated into the endoplasmic reticulum. Eur. J. Immunol. 27, 1685-1690 (1997).
27. Matsumura, M., Fremont, D.H., Peterson, P.A. & Wilson, I.A. Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science 257, 927-934 (1992).
28. Speir, J.A., Stevens, J., Joly, E., Butcher, G.W. & Wilson, I.A. Two different, highly exposed, bulged structures for an unusually long peptide bound to rat MHC class I RT1-Aa. Immunity 14, 81-92 (2001).
29. Stern, L.J. et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368, 215-221 (1994).
30. Mohan, J.F. & Unanue, E.R. A novel pathway of presentation by class II-MHC molecules involving peptides or denatured proteins important in autoimmunity. Mol. Immunol. 55, 166-168 (2013).
31. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G. & Rammensee, H.G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290-296 (1991).
32. Madden, D.R., Garboczi, D.N. & Wiley, D.C. The antigenic identity of peptide- MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 75, 693-708 (1993).
33. Hanada, K., Yewdell, J.W. & Yang, J.C. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427, 252-256 (2004).
34. Vigneron, N. et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 304, 587-590 (2004).
35. Warren, E.H. et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 313, 1444-1447 (2006).
36. Grommé, M. et al. The rational design of TAP inhibitors using peptide substrate modifications and peptidomimetics. Eur. J. Immunol. 27, 898-904 (1997).
37. Andersen, M.H. et al. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J. Immunol. 163, 3812-3818 (1999).
38. Haurum, J.S. et al. Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J. Exp. Med. 190, 145-150 (1999).
39. Altrich-VanLith, M.L. et al. Processing of a class I-restricted epitope from tyrosinase requires peptide N-glycanase and the cooperative action of endoplasmic reticulum aminopeptidase 1 and cytosolic proteases. J. Immunol. 177, 5440-5450 (2006).
40. Wang, Y. & Dai, S. Structural basis of metal hypersensitivity. Immunol. Res. 55, 83-90 (2013).
41. Illing, P.T. et al. Immune self-reactivity triggered by drug-modified HLApeptide repertoire. Nature 486, 554-558 (2012).
42. Romagnoli, P., Labhardt, A.M. & Sinigaglia, F. Selective interaction of Ni with an MHC-bound peptide. EMBO J. 10, 1303-1306 (1991).
43. Falta, M.T. et al. Identification of beryllium-dependent peptides recognized by CD4+ T cells in chronic beryllium disease. J. Exp. Med. 1403-1418. (2013).
44. Sollid, L.M., Qiao, S.W., Anderson, R.P., Gianfrani, C. & Koning, F. Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics 64, 455-460 (2012).
45. Wucherpfennig, K.W. & Hafler, D.A. A review of T-cell receptors in multiple sclerosis: clonal expansion and persistence of human T-cells specific for an immunodominant myelin basic protein peptide. Ann. NY Acad. Sci. 756, 241-258 (1995).
46. Mallone, R., Brezar, V. & Boitard, C. T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives. Clin. Dev. Immunol. 2011, 513210 (2011).
47. Thomson, G. et al. Genetic heterogeneity, modes of inheritance, and risk estimates for a joint study of Caucasians with insulin-dependent diabetes mellitus. Am. J. Hum. Genet. 43, 799-816 (1988).
48. Stritesky, G.L., Jameson, S.C. & Hogquist, K.A. Selection of self-reactive T cells in the thymus. Annu. Rev. Immunol. 30, 95-114 (2012).
49. Lyons, D. S. et al. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 5, 53-61 (1996).
50. Larché, M. & Wraith, D.C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 11, S69-S76 (2005).
51. Kenter, G.G. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838-1847 (2009).
52. Paulis, L.E., Mandal, S., Kreutz, M. & Figdor, C.G. Dendritic cell-based nanovaccines for cancer immunotherapy. Curr. Opin. Immunol. 25, 389-395 (2013).
53. Kast, W.M. et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. USA 88, 2283-2287 (1991).
54. DeNardo, S.J. et al. Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. Clin. Cancer Res. 9, 3854S-3864S (2003).
55. Bontrop, R.E. Comparative genetics of MHC polymorphisms in different primate species: duplications and deletions. Hum. Immunol. 67, 388-397 (2006).
56. Strominger, J.L. & Wiley, D.C. The 1995 Albert Lasker Medical Research Award. The class I and class II proteins of the human major histocompatibility complex. J. Am. Med. Assoc. 274, 1074-1076 (1995).
57. Pircher, H. et al. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 346, 629-633 (1990).
58. Jorritsma, A., Schumacher, T.N. & Haanen, J.B. Immunotherapeutic strategies: the melanoma example. Immunotherapy 1, 679-690 (2009).
59. Khan, S. et al. Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. Mol. Immunol. 46, 1084-1091 (2009).
60. Khan, S. et al. Distinct uptake mechanisms but similar intracellular processing of two different Toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol. Chem. 282, 21145-21159 (2007).
61. Neefjes, J.J., Smit, L., Gehrmann, M. & Ploegh, H.L. The fate of the three subunits of major histocompatibility complex class I molecules. Eur. J. Immunol. 22, 1609-1614 (1992).
62. Engels, B. et al. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 23, 516-526 (2013).
63. Valeur, E. & Bradley, M. Amide bond formation: beyond the myth of coupling reagents. Chem. Soc. Rev. 38, 606-631 (2009).
64. El-Faham, A. & Albericio, F. Peptide coupling reagents, more than a letter soup. Chem. Rev. 111, 6557-6602 (2011).
65. Kammertoens, T. & Blankenstein, T. It's the peptide-MHC affinity, stupid. Cancer Cell 23, 429-431 (2013).
66. Townsend, A.R. et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44, 959-968 (1986).
67. Fremont, D.H., Matsumura, M., Stura, E.A., Peterson, P.A. & Wilson, I.A. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. Science 257, 919-927 (1992).
68. Andersson, I.E., Dzhambazov, B., Holmdahl, R., Linusson, A. & Kihlberg, J. Probing molecular interactions within class II MHC Aq/glycopeptide/T-cell receptor complexes associated with collagen-induced arthritis. J. Med. Chem. 50, 5627-5643 (2007).
69. Reinelt, S. et al. β-amino acid scan of a class I major histocompatibility complex-restricted alloreactive T-cell epitope. J. Biol. Chem. 276, 24525-24530 (2001).